Meeting
2023 ASCO Annual Meeting
Phase III study to evaluate the efficacy and safety of GLSI-100 (GP2 + GM-CSF) in breast cancer patients with residual disease or high-risk PCR after both neoadjuvant and postoperative adjuvant anti-HER2 therapy: Flamingo-01.
Authors
Snehal Patel
Greenwich LifeSciences, Stafford, TX
Snehal Patel , Jaye Thompson , Mira Patel , F. Joseph Daugherty , Mothaffar F. Rimawi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Clinical Trial Registration Number
NCT05232916
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS617)
DOI
10.1200/JCO.2023.41.16_suppl.TPS617
Abstract #
TPS617
Poster Bd #
446a
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A randomized, multicenter, placebo-controlled, phase III study to evaluate the efficacy and safety of HER2/neu peptide GLSI-100 (GP2 + GM-CSF) in patients with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy, Flamingo-01.
First Author: Snehal Patel
Poster
2023 ASCO Annual Meeting
Efficacy and safety of niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer who had measurable residual disease: A post-hoc subgroup analysis of the PRIME study.
First Author: Beihua Kong
Poster
2023 ASCO Annual Meeting
State-of-the-art management of HER2-negative early breast cancer: Treatment patterns among healthcare professionals and concordance with expert recommendations.
First Author: Marie N. Becker
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Safety and efficacy of immunotherapy in combination with epigenetic therapy in an esophageal adenocarcinoma model.
First Author: Ashten Omstead